Compare Gilead Sciences, Inc. (GILD) vs QUALCOMM, Inc. (QCOM) Price & Performance

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Qualcomm (QCOM) trades at $162.68, down 3.09% amid broader semiconductor sector pressure. The stock shows mixed signals with bearish technical indicators but strong fundamentals including recent earnings beats and a 21.01% net income margin. Recent news highlights Qualcomm's strategic pivot toward AI and data centers, though competition from Nvidia's new PC chip has sparked investor concerns. The company maintains solid cash flow generation of $14.01B from operations in 2025 and continues dividend payments.

Qualcomm presents a compelling value opportunity with a P/E of 18.53 below sector averages, supported by analyst consensus price target of $200.56 implying 23% upside. Key risks include smartphone market softness and intensifying AI competition. The company's diversification into automotive and data centers provides growth catalysts, though execution risks remain. Current levels offer attractive entry for long-term investors seeking exposure to semiconductor and AI infrastructure.